The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.
Intelligent MoS2 Nanotheranostic for Targeted and Enzyme-/pH-/NIR-Responsive Drug Delivery To Overcome Cancer Chemotherapy Resistance Guided by PET Imaging
Abstract
Chemotherapy resistance remains a major hurdle for cancer therapy in clinic because of the poor cellular uptake and insufficient intracellular release of drugs. Herein, an intelligent, multifunctional MoS 2 nanotheranostic (MoS 2 -PEI-HA) ingeniously decorated with biodegradable hyaluronic acid (HA) assisted by polyethyleneimine (PEI) is reported to combat drug-resistant breast cancer (MCF-7-ADR) after loading with the chemotherapy drug doxorubicin (DOX). HA can not only target CD44-overexpressing MCF-7-ADR but also be degraded by hyaluronidase (HAase) that is concentrated in the tumor microenvironment, thus accelerating DOX release. Furthermore, MoS 2 with strong near-infrared (NIR) photothermal conversion ability can also promote the release of DOX in the acidic tumor environment at a mild 808 nm laser irradiation, achieving a superior antitumor activity based on the programmed response to HAase and NIR laser actuator. Most importantly, HA targeting combined with mild NIR laser stimuli, rather than using hyperthermia, can potently downregulate the expression of drug-resistance-related P-glycoprotein (P-gp), resulting in greatly enhanced intracellular drug accumulation, thus achieving drug resistance reversal. After labeled with 64 Cu by a simple chelation strategy, MoS 2 was employed for real-time positron emission tomography (PET) imaging of MCF-7-ADR tumor in vivo. This multifunctional nanoplatform paves a new avenue for PET imaging-guided spatial–temporal-controlled accurate therapy of drug-resistant cancer.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Cancer drug resistance: an evolving paradigm
Holohan, C., Van Schaeybroeck, S., Longley, D. B., & Johnston, P. G. (2013) · Nature Reviews Cancer · doi:10.1038/nrc3599 · Cited by 4,681
Redox-responsive polymers for drug delivery: from molecular design to applications
Huo, M., Yuan, J., Tao, L., & Wei, Y. (2014) · Polym. Chem. · doi:10.1039/c3py01192e · Cited by 561
Cited by
Photothermal therapy and photoacoustic imaging via nanotheranostics in fighting cancer
Liu, Y., Bhattarai, P., Dai, Z., & Chen, X. (2019) · Chemical Society Reviews · doi:10.1039/c8cs00618k · Cited by 2,904
Feng, L., Xie, R., Wang, C., Gai, S., He, F., Yang, D., Yang, P., & Lin, J. (2018) · ACS Nano · doi:10.1021/acsnano.8b05042 · Cited by 422
2D MoS2‐Based Nanomaterials for Therapeutic, Bioimaging, and Biosensing Applications
Yadav, V., Roy, S., Singh, P., Khan, Z., & Jaiswal, A. (2019) · Small · doi:10.1002/smll.201803706 · Cited by 361
Tumor microenvironment-responsive intelligent nanoplatforms for cancer theranostics
Gong, F., Yang, N., Wang, X., Zhao, Q., Chen, Q., Liu, Z., & Cheng, L. (2020) · Nano Today · doi:10.1016/j.nantod.2020.100851 · Cited by 359
Emerging 2D nanomaterials for biomedical applications
Murali, A., Lokhande, G., Deo, K. A., Brokesh, A., & Gaharwar, A. K. (2021) · Materials Today · doi:10.1016/j.mattod.2021.04.020 · Cited by 349
Metadata
- Authors
- Dong, X., Yin, W., Zhang, X., Zhu, S., He, X., Yu, J., Xie, J., Guo, Z., Yan, L., Liu, X., Wang, Q., Gu, Z., & Zhao, Y.
- Venue
- ACS Applied Materials & Interfaces
- Publisher
- American Chemical Society (ACS)
- Published
- 2018-01-22
- Volume
- 10
- Issue
- 4
- Pages
- 4271-4284
- ISSN
- 1944-8244 (ISSN-L)
- 1944-8252
- OpenAlex
- W2783429258
- Cited by
- 158
- References
- 2
- FWCI
- 7.93
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Intelligent MoS2 Nanotheranostic for Targeted and Enzyme-/pH-/NIR-Responsive Drug Delivery To Overcome Cancer Chemotherapy Resistance Guided by PET Imaging. https://app.cochat.ai/papers/10.1021/acsami.7b17506
- The paper
- Dong, X., Yin, W., Zhang, X., Zhu, S., He, X., Yu, J., Xie, J., Guo, Z., Yan, L., Liu, X., Wang, Q., Gu, Z., & Zhao, Y. (2018). Intelligent MoS2 Nanotheranostic for Targeted and Enzyme-/pH-/NIR-Responsive Drug Delivery To Overcome Cancer Chemotherapy Resistance Guided by PET Imaging. ACS Applied Materials & Interfaces. https://doi.org/10.1021/acsami.7b17506
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.